Merck & Co., Inc. Announces Completion of NovaCardia, Inc. Acquisition

Published: Sep 11, 2007

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. today announced that it has successfully completed the acquisition of NovaCardia, Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. This acquisition adds rolofylline (KW-3902), NovaCardia's investigational Phase III compound for acute heart failure to Merck's pipeline.

Back to news